Compare ARVN & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARVN | NAVI |
|---|---|---|
| Founded | 2015 | 1973 |
| Country | United States | United States |
| Employees | N/A | 670 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.0M | 771.2M |
| IPO Year | 2018 | N/A |
| Metric | ARVN | NAVI |
|---|---|---|
| Price | $10.13 | $8.05 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 20 | 7 |
| Target Price | ★ $15.35 | $12.14 |
| AVG Volume (30 Days) | 670.7K | ★ 844.6K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 7.78% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | $74.32 |
| Revenue Next Year | N/A | $15.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.90 | $7.86 |
| 52 Week High | $14.22 | $16.07 |
| Indicator | ARVN | NAVI |
|---|---|---|
| Relative Strength Index (RSI) | 31.91 | 30.14 |
| Support Level | $9.02 | $7.86 |
| Resistance Level | $10.18 | $8.40 |
| Average True Range (ATR) | 0.67 | 0.24 |
| MACD | -0.22 | 0.09 |
| Stochastic Oscillator | 4.18 | 33.33 |
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.